医药行业周报：瑞思迈业绩超市场预期，关注呼吸产业链

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" [2] Core Viewpoints - The pharmaceutical index has shown a significant rebound, with a weekly increase of 3.11%, outperforming the market by 2.32 percentage points [2][12] - The report emphasizes the potential for recovery in the fourth quarter, particularly in the medical device sector, and suggests focusing on companies like Mindray Medical, Kanghua Medical, and others [1][4] - The report highlights the strong performance of ResMed, which exceeded market expectations, and recommends attention to the respiratory industry chain [4][24] Summary by Sections Weekly Performance Analysis - From October 21 to October 25, the Shanghai and Shenzhen 300 Index rose by 0.79%, while the pharmaceutical index increased by 3.11% [1][2] - The number of stocks that rose during the week was 434, while 58 stocks fell [2][12] Investment Suggestions - Focus on sectors expected to rebound in Q4, such as medical devices and quality leaders in specific fields [1][4] - Suggested stocks include ResMed, Yuyue Medical, and others in the home respiratory machine supply chain [4][24] Sector Performance - The report details the performance of various sub-sectors, with medical services up by 5.2%, medical devices by 4.0%, and chemical raw materials by 3.5% [2][15] - Year-to-date, the pharmaceutical index has decreased by 9.11%, ranking it among the bottom three sectors in the Shenwan classification [4][12] Key Companies and Investment Portfolio - Current investment portfolio includes companies like Hehuang Pharmaceutical, Kanghua Medical, and others [3][25] - The October investment portfolio features Yuyue Medical, Sanofi Biological, and others [3][25]